European Commission has approved VEOZATM 45 mg once daily for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Astellas Pharma announced that the European Commission (EC) on December 7 approved VEOZATM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, also known as hot flashes and/or night sweats,…